

Multi-disciplinary discussion for differential diagnosis

Bruce Hsin-Kuo Ko, MD, PhD.

Division of Respiratory Therapy, Department of Chest Medicine,
Taipei Veterans General Hospital, Taiwan

13:30- 13:50, 8 Dec., 2019

Case from Dr. Kang-Cheng Su

Patient Information

- Mr. Cheng, 68 yr male, never smoker, 170cm, BW 65kg, BMI 22.4
- Presentation: seizure for 5 min at 19:00, 2019/9/18
- PE: bilateral basal crackle, wheezing (-), rhonchi/rales (+), clubbing fingers (+)
- Employment/social history/environmental exposures: retired teacher; relevant infections: none
- Concomitant diseases:
 - Follicular mixed cell lymphoma, s/p CHOP x6 in 2003
 - Hepatitis B carrier, under Entecavir
 - Gout, HTN, Type 2 diabetes mellitus, HbA1c 8.4 (2019/10/07)
- RUL adenocarcinoma, diagnosed on 2014/11, with brain metastasis, initial cT3N0M1b, stage IV, EGFR exon 19 deletion

2014.11
adenocarcinoma

2015.1

2014.11.25



2016.1

2014.11
adenocarcinoma

2015.3.26 (cough, fever)

2015.1


2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS

2016.1



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9


s/p Afatinib

2015.2.4

s/p GKRS

2016.1

2015.3.26 (cough, fever)



2014.11
adenocarcinoma

2015.3.26 (cough, fever)


2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS



2016.1

2014.11
adenocarcinoma

2015.3.26 (cough, fever)


2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS



2016.1

2014.11
adenocarcinoma

2015.3.26 (cough, fever)


2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS



2016.1

2014.11
adenocarcinoma

2015.3.26 (cough, fever)


2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS



2016.1

2014.11
adenocarcinoma

2015.3.26 (cough, fever)

2015.1


2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS

2016.1



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS

2016.1

2015.3.26 (cough, fever)



2014.11
adenocarcinoma

2015.3.26 (cough, fever)


2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS



2016.1

2014.11
adenocarcinoma

2015.3.26 (cough, fever)

2015.1


2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS

2016.1



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib


2015.2.4

s/p GKRS

2015.6.4 – 2015.10.15

s/p Cisplatin +
Pemetrexed

2015.10.21 (productive cough)



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4


s/p GKRS

2015.6.4 – 2015.10.15

s/p Cisplatin +
Pemetrexed

2016.1

2015.10.21 (productive cough)



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4


s/p GKRS

2015.6.4 – 2015.10.15

s/p Cisplatin +
Pemetrexed

2016.1

2015.10.21 (productive cough)



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4


s/p GKRS

2015.6.4 – 2015.10.15

s/p Cisplatin +
Pemetrexed

2016.1

2015.10.21 (productive cough)



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4


s/p GKRS

2015.6.4 – 2015.10.15

s/p Cisplatin +
Pemetrexed

2016.1

2015.10.21 (productive cough)



2014.11
adenocarcinoma

2015.10.21 (productive cough)

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib


2015.2.4

s/p GKRS

2015.6.4 – 2015.10.15

s/p Cisplatin +
Pemetrexed

2016.1



2014.11
adenocarcinom

2015.1

2015.1.29 – 201

s/p Afatinib

2015.2.4


s/p GKRS

2015.6.4 – 2015

s/p Cisplatin +
Pemetrexed

2016.1

2015.10.21 (productive cough)



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4


s/p GKRS

2015.6.4 – 2015.10.15

s/p Cisplatin +
Pemetrexed

2016.1

2015.10.21 (productive cough)



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4/9

s/p Afatinib

2015.2.4

s/p GKRS

2015.6.4 – 2015.10.15

s/p Cisplatin +
Pemetrexed

2016.1

2015.10.21 (productive cough)



2014.11
adenocarcinoma

2015.1

2015.1.29 – 2015.4.9

s/p Afatinib

2015.2.4

s/p GKRS

2015.6.4 – 2015.10.15


s/p Cisplatin +
Pemetrexed

2016.1

2016.1.9

Brain MRI = PD

2015.10.21 (productive cough)




2016.1

2016.2.22- 2016.11.14
s/p Erlotinib

2016.10.17


2017.1



2016.1

2016.10.17

2016.2.22- 2016.11.14
s/p Erlotinib




2017.1

2016.1

2016.2.22- 2016
s/p Erlotinib

2016 10.17




2017.1

2016.1

2016.2.22- 2016.11.14
s/p Erlotinib

2016.10.17



2017.1

2016.1

2016.2.22- 2016.11.14
s/p Erlotinib

2016.10.17




2017.1

2016.1

2016.2.22- 2016.11.14
s/p Erlotinib

2016.10.17


2017.1



2016.1

2016.2.22- 2016.11.14
s/p Erlotinib

2016.10.17



2017.1




2016.1

2016.2.22- 2016.11.14
s/p Erlotinib

2016.10.17

2017.1



2016.1

2016.2.22- 2016.11.14
s/p Erlotinib

< 2016.11.26 influenza A


2016.11.21- 2016.12.12
s/p Vinorelbine +
Gemcitabine C1-2



2017.1

2017.6.4
Brain MRI = PD
2017.7.5 GKRS

< 2017.7.4 pneumonitis



2018.1

< s/p pred 1# bid, Norvasc,
codeine, Fluimucil

< 2018.2.19 ILD-AE



2019.1

< 2019.6.11 ILD-^T

< 2019.8.21 ILD-

< 2019.9.19 Seizure
+ ETT and
Admission


2019.10.18




2018.1

< s/p pred 1# bid
codeine, Fluimucil

< 2018.2.19 ILD-



2019.10.18





2019.1

< 2019.6.11 ILD-

< 2019.8.21 ILD-

< 2019.9.19 Seizure
+ ETT and
Admission




2018.1

< s/p pred 1# bic
codeine, Fluim!
+ ETT and
Admission

2019.10.18

< 2018.2.19 ILD-






2019.1

< 2019.6.11 ILD-

< 2019.8.21 ILD-


< 2019.9.19 Seizure
+ ETT and
Admission



2018.1

< s/p pred 1# bic
codeine, Fluim

< 2018.2.19 ILD-



2019.10.18





2019.1

< 2019.6.11 ILD-

< 2019.8.21 ILD-

< 2019.9.19 Seizure
+ ETT and
Admission



2018.1

< s/p pred 1# bic
codeine, Fluim

< 2018.2.19 ILD-





2019.1

< 2019.6.11 ILD-,

< 2019.8.21 ILD-,

< 2019.9.19 Seizure
+ ETT and
Admission

2019.10.18



2018.1

< s/p pred 1# bid
codeine, Fluimucil

< 2018.2.19 ILD-/-





2019.1

< 2019.6.11 ILD-/-

< 2019.8.21 ILD-/-

< 2019.9.19 Seizure
+ ETT and
Admission


2019.10.18




2018.1

< s/p pred 1# bic
codeine, Fluimⁿ

< 2018.2.19 ILD-



2019.10.18





2019.1

< 2019.6.11 ILD-

< 2019.8.21 ILD-

< 2019.9.19 Seizure
+ ETT and
Admission



Lab data

2019.9.19

- Wbc 8500, Hb 14.9, PLT 183k, Band 2%, S/L (%) 75/9
- Alb 3.5 mg/dl, bun/cre 25/0.85, T bili 0.59, ALT 46, Na/K 137/5.2, CK 47, CRP 0.42

2019.10.16

- ANA = 1:320 nuclear (+)
- Sm/RNP, SSA/SSB, Scl-70, ANCA, anti-GBM Ab, anti-dsDNA (all negative)
- C3/C4 46.1(L)/8.3(L), IgG/A/M 355(L)/82/34(L), ESR 5

Parameter	2014.12.5	2018.2.23	2019.4.2	Parameter	2019.4.2
FVC (L)	3.04	1.22	1.0	VT (L)	0.49
FVC (%pred)	81	33	28	Z5 (%pred)	0.45 (145%)
FEV ₁ (L)	2.64	1.2	0.82	R5 (%pred)	0.45 (145%)
FEV1(%pred)	95	46	31	R20	0.30 (111%)
FEV ₁ /FVC (%)	86	99	82	R5-20	0.15
TLC (%pred)		64	32	X5 (ref)	-0.02 (-0.03)
RV (%pred)		120	39	Rf	22.96
RV/TLC (%)		187	123	AX	0.99
ERV (%pred)		28	33		
IC (%pred)		37	25		
VC (%pred)		33	28		
PEF (L/sec)		3.24	3.9		
PEF (%pred)		39	47		
DLCO (%pred)	86				
DLCO/VA (%pred)	112				
6MWT					

Discussion

- Usual interstitial pneumonia and IPF?
- Undifferentiated CTD-ILD
- Drug-ILD
- Others: